This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Rickets, active / Nutritional rickets / Vitamin D deficiency rickets활동성 구루병 (영아·연소성 골연화증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E55.0 (Rickets, active) | Synonym codes: infantile osteomalacia, juvenile osteomalacia | Special Copayment Reduction: V207 (rare disease)
B. SynonymsActive rickets (active rickets), infantile osteomalacia, juvenile osteomalacia, vitamin D deficiency rickets, nutritional rickets, calcium deficiency rickets
C. Adult onsetA childhood disease, but can also present in adulthood as vitamin D deficiency osteomalacia. Presents as osteomalacia in pregnant and breastfeeding women and adults with insufficient sun exposure (adult counterpart disease).
1. HistoryDescription of a rickets epidemic associated with industrialization in 17th-century England → discovery of vitamin D by McCollum in 1922 → preventive effect of ultraviolet light·fish oil established in the 1930s → vitamin D metabolic pathway elucidated in the 1970s–80s → common in Korea until the 1980s–90s, but declined thereafter.
2. CausesVitamin D deficiency (lack of sunlight, insufficient dietary intake, exclusive breastfeeding), calcium deficiency (dietary), malabsorption (Crohn's disease, celiac disease), abnormal vitamin D metabolism (liver·kidney disease, certain drugs). Rarely hereditary (VDDR, etc.).
3. GeneticsNutritional rickets is nonhereditary. Hereditary forms: vitamin D-dependent rickets type 1 (VDDR1, CYP27B1 variants), type 2 (VDDR2, VDR variants), hypophosphatemic rickets (PHEX variants; X-linked). Nutritional rickets is driven by environmental·dietary factors.
4. General epidemiologyChildhood rickets worldwide has high prevalence in Africa·South Asia·the Middle East. In Korea, nutritional rickets is rare, but cases have been reported in immigrant children from developing countries. Children with limited sunlight·exclusive breastfeeding·insufficient vitamin D supplementation are a high-risk group.
5. PathophysiologyVitamin D deficiency → decreased serum Ca²⁺·Pi → increased PTH (secondary hyperparathyroidism) → impaired calcium deposition at the growth plate → excessive accumulation of immature bone matrix (osteoid) → growth plate widening, skeletal deformity. Hypocalcemia → increased neuromuscular excitability.
6. SymptomsInfancy: hypocalcemia (seizures, laryngospasm, carpopedal spasm). Childhood: growth failure, skeletal deformities (genu varum/genu valgum, chest deformity), muscle weakness, bone pain, delayed tooth eruption, gait disturbance.
7. SignsCraniotabes, frontal bossing, parietal bossing, chest deformities (rachitic rosary, Harrison's groove), widening of the wrists·ankles (growth plate widening), genu varum/genu valgum, elevated ALP·PTH, decreased Ca·Pi, decreased 25(OH)D, cupped growth plates on X-ray.
8. ScreeningScreening of high-risk groups (exclusive breastfeeding, lack of sunlight, children with dark skin, malabsorption disorders): serum 25(OH)D, ALP, Ca, Pi, PTH. Some countries include it in newborn screening (early detection in some).
9. DiagnosisSerum 25(OH)D (<20ng/mL deficiency), ALP (markedly elevated), Ca, Pi, PTH, urine calcium/phosphate. Wrist·knee X-rays (growth plate widening, cupping, decreased bone density, bowing of the diaphysis). If needed, measurement of 1,25(OH)₂D, FGF-23.
10. TreatmentNutritional: vitamin D (cholecalciferol 2,000–6,000IU/day initial dose; or stoss therapy) + calcium supplementation (500mg/day). Active vitamin D (calcitriol) is used in hereditary forms or with accompanying renal failure. Increased sun exposure. Orthopedic correction for severe skeletal deformities.
11. PrognosisMost recover completely with early treatment. If treatment is delayed, skeletal deformities may become permanent. After vitamin D supplementation, biochemical markers normalize within weeks and radiographic findings within months. Minimal effect on final height.
12. PreventionVitamin D supplementation for newborns (400IU/day, including breastfed infants). Vitamin D supplementation for pregnant women. Sufficient dietary calcium intake. Sun exposure (15–30 minutes a day). Vitamin D fortification of infant formula. Public health prevention strategies in high-risk areas.
13. ReferencesMunns CF et al. Global Consensus Rickets (2016, JCEM) and 9 others

1. History

Rickets epidemics in Europe during the industrial era

The clinical description of rickets dates back to 17th-century England. De Rachitide, co-authored in 1645 by Francis Glisson, George Bate, and Assuerus Regemorter, was the first systematic scholarly description of rickets, describing in Latin the skeletal deformity disease of children that was then rapidly increasing in England. After the Industrial Revolution, in the industrialized cities of England, Northern Europe, and North America, reduced sunlight combined with nutritional imbalance made childhood rickets a very common disease, with high incidence reported particularly among children of the urban poor and in factory districts. In the late 19th century, some physicians empirically discovered that administration of fish oil (cod liver oil) and exposure to sunlight were effective for rickets, but the mechanism was unknown.

In the early 20th century, research elucidating the relationship between nutrients and disease was actively conducted. Between 1914 and 1922, Elmer McCollum and Marguerite Davis discovered the existence of fat-soluble vitamins, and in 1922 McCollum, through an experiment showing that heating and oxidizing fish oil destroys vitamin A activity but leaves the antirachitic effect intact, first clearly demonstrated that the antirachitic substance was a separate fat-soluble factor distinct from vitamin A (then called 'vitamin D'). Subsequently, in the 1930s, the photochemical reaction by which ultraviolet irradiation converts a cholesterol derivative in the skin into vitamin D was elucidated, and as vitamin D-fortified milk, fish oil, and UV-irradiated foods came to be used to prevent rickets, the incidence of rickets declined sharply in developed countries.

Elucidation of the vitamin D metabolic pathway and modern understanding

In the 1970s, it was established that vitamin D functions as a hormone. Vitamin D₃ (cholecalciferol), produced in the skin or ingested in the diet, undergoes 25-hydroxylation in the liver to become 25(OH)D₃ (calcifediol), which is then converted by renal 1α-hydroxylase (CYP27B1) into the active form 1,25(OH)₂D₃ (calcitriol). Calcitriol binds to the nuclear vitamin D receptor (VDR), promoting intestinal absorption of calcium and phosphate, regulating renal reabsorption, and regulating the transcription of genes involved in bone mineralization. With the elucidation of this metabolic pathway, the molecular mechanisms of hereditary vitamin D-dependent rickets type 1 (CYP27B1 defect) and type 2 (VDR defect) were understood, and the clinical use of calcitriol became possible.

In Korea, rickets associated with nutritional deficiency was not uncommon until the 1970s–80s, but the incidence decreased greatly as nutritional status improved with economic growth and vitamin D-fortified foods became widespread. However, due to the increase in exclusive breastfeeding, reduced sun exposure from more indoor living, and the increase in immigrant families, it still occurs sporadically in high-risk groups. Its designation as Special Copayment Reduction V207 is to support medical care for active rickets as a whole, including severe rare forms (including hereditary rickets).


2. Causes

Nutritional rickets due to vitamin D deficiency

The most common cause of active rickets (E55.0) is vitamin D deficiency, which in turn is divided into three pathways. First, lack of sunlight: about 80–90% of the body's vitamin D is supplied through the photochemical reaction in which ultraviolet B (UV-B, 290–320nm) converts 7-dehydrocholesterol in the skin into pre-vitamin D₃. Dark skin (increased melanin), high-latitude regions, a predominantly indoor lifestyle, and routine use of sunscreen reduce skin synthesis. Second, insufficient dietary intake: insufficient intake of foods rich in vitamin D (oily fish, egg yolk, fortified foods). Third, exclusive breastfeeding: the vitamin D content of breast milk is very low (about 20–40IU/L), so infants fed only breast milk without vitamin D supplementation are a high-risk group for rickets.

Calcium deficiency and malabsorption

Calcium deficiency rickets occurs when dietary calcium intake is extremely insufficient even if vitamin D levels are normal, and is common in some parts of Africa. In this form, 25(OH)D levels are normal but serum calcium is low and PTH is markedly elevated; it does not heal with vitamin D supplementation alone, and calcium supplementation is essential. Rickets due to malabsorption can occur in Crohn's disease, celiac disease, hepatobiliary disease, exocrine pancreatic insufficiency, after bariatric surgery, etc. In fat malabsorption, absorption of the fat-soluble vitamins (A, D, E, K) is impaired simultaneously.

Disorders of vitamin D metabolism

In liver disease (cirrhosis, cholestasis), 25-hydroxylation capacity may be reduced, and in kidney disease (chronic kidney disease), 1α-hydroxylation is reduced, decreasing calcitriol production. Among drugs, antiepileptics (phenytoin, carbamazepine, phenobarbital) and antituberculosis drugs (rifampin) accelerate vitamin D metabolism in the liver, lowering 25(OH)D and 1,25(OH)₂D levels. Hereditary forms include vitamin D-dependent rickets (VDDR) type 1 (1α-hydroxylase deficiency due to CYP27B1 variants) and type 2 (VDR variants), and X-linked hypophosphatemic rickets (XLH, PHEX variants) forms a separate category whose main mechanism is renal phosphate wasting due to excess FGF-23.


3. Genetics

Nonhereditary nature of nutritional rickets

Active rickets of E55.0, particularly nutritional rickets, is basically an acquired disease due to environmental and dietary factors and does not follow a specific Mendelian inheritance pattern. However, polymorphisms in genes related to vitamin D metabolism and its receptor may affect individual susceptibility to vitamin D deficiency. For example, the BsmI, ApaI, and TaqI polymorphisms of the VDR gene have been proposed to be associated with serum vitamin D levels and susceptibility to developing rickets.

Molecular genetics of hereditary rickets

Among hereditary forms of rickets, vitamin D-dependent rickets type 1 (VDDR1A) is caused by variants in the CYP27B1 gene (12q14.1) and is inherited in an autosomal recessive manner. CYP27B1 encodes 1α-hydroxylase, which converts 25(OH)D into the active form calcitriol (1,25(OH)₂D) in the kidney and some immune cells. When this enzyme is deficient, serum 25(OH)D is normal but calcitriol is low, with decreased Ca·Pi, markedly elevated PTH, and rickets. It is treated with calcitriol administration. VDDR2 (HVDRR) is caused by variants in the VDR gene (12q13) and, due to a calcitriol receptor defect, causes treatment-resistant rickets that does not respond even to very high doses of calcitriol. In this form, alopecia appearing together with rickets is a characteristic finding.

X-linked hypophosphatemic rickets (XLH) is caused by variants in the PHEX gene (Xp22.2-p21.1) and is inherited in an X-linked dominant manner. PHEX encodes an endopeptidase that promotes the degradation of fibroblast growth factor 23 (FGF-23); when PHEX is deficient, FGF-23 accumulates excessively, inhibiting renal phosphate reabsorption and also impairing calcitriol synthesis. As a result, rickets and osteomalacia develop along with hypophosphatemia. Recently, burosumab, a neutralizing antibody against FGF-23, was approved as a treatment for XLH.


4. General epidemiology

Global epidemiology

Nutritional rickets remains a public health problem worldwide, with high prevalence reported particularly in sub-Saharan Africa, South Asia (India, Pakistan, Bangladesh), the Middle East, and Southeast Asia. According to the 2016 Global Consensus report, the prevalence of nutritional rickets in these regions ranges from a few to several dozen per 1,000 children depending on the region. There is an epidemiological pattern dividing it into an African type, in which calcium deficiency is the main cause, and a European·Asian type, in which vitamin D deficiency is the main cause. In developed countries, rickets is reported in exclusively breastfed infants who have not received vitamin D supplementation, especially children with dark skin from immigrant families.

Epidemiology in Korea

In Korea, nutritional rickets was not uncommon before the 1970s–80s, but it is now rare owing to economic growth, improved nutrition, and the spread of vitamin D-fortified formula. Recently, however, along with the trend emphasizing exclusive breastfeeding, cases of rickets and hypocalcemic seizures due to insufficient vitamin D supplementation have been reported intermittently. Vitamin D deficiency is also more common in children of multicultural families, particularly children of nationalities with darker skin. The Korean Society of Pediatric Endocrinology recommends vitamin D supplementation of 400IU/day from immediately after birth for breastfed infants. Hereditary rickets (VDDR, XLH) is very rare, and a small number of patients nationwide are managed at specialized institutions.


5. Pathophysiology

Regulation of vitamin D-calcium-phosphate homeostasis

Calcitriol (1,25(OH)₂D₃), the active form of vitamin D, promotes calcium absorption in the small intestine by increasing the expression of TRPV6 (epithelial calcium channel) and calbindin-D9k, and promotes phosphate absorption by increasing NaPi-2b expression. In the kidney, it increases calcium reabsorption and regulates phosphate reabsorption. Parathyroid hormone (PTH) increases renal calcium reabsorption, promotes phosphate excretion, and stimulates renal CYP27B1 to increase calcitriol production. PTH also activates osteoclasts through RANKL expression, replenishing serum calcium through bone resorption.

Pathological mechanism of rickets

When vitamin D deficiency occurs, intestinal calcium absorption decreases and serum calcium falls, and in response PTH rises compensatorily (secondary hyperparathyroidism). The elevated PTH increases renal phosphate excretion, so serum phosphate also falls. In the state of hypocalcemia·hypophosphatemia, calcification of growth plate chondrocytes cannot proceed normally, and as a result immature bone matrix (osteoid) accumulates excessively at the growth plate. The growth plate becomes abnormally widened and irregular in shape, producing the characteristic 'cupping' and 'fraying' deformities on X-ray. Already formed cortical bone also cannot be sufficiently mineralized, resulting in osteomalacia, and with weight bearing, skeletal deformities (genu varum, genu valgum, scoliosis, etc.) progress.

Hypocalcemia increases neuromuscular excitability and in infancy can present as laryngospasm, tetany, and hypocalcemic seizures, which can be life-threatening acute complications of rickets. In severe hypocalcemia, heart failure due to reduced myocardial contractility has also been reported. In tissues other than bone, calcitriol plays various roles, such as regulating immune function, regulating cell proliferation and differentiation, and muscle function, so vitamin D deficiency can also have systemic effects such as increased susceptibility to infection, muscle weakness, and increased risk of autoimmune disease.


6. Symptoms

Symptoms in infancy (6 months to 2 years of age)

The symptoms of vitamin D deficiency rickets differ by age of onset. In infancy (especially 6 months to 2 years of age), symptoms are prominent because mineral supply is insufficient relative to rapid growth. Symptoms related to hypocalcemia may appear early, and carpopedal spasm, stridor due to laryngospasm, and hypocalcemic seizures may be the first symptoms. This is often the acute presentation of vitamin D deficiency rickets, corresponding to cases in which an exclusively breastfed infant a few months old is brought to the emergency department with a sudden seizure. Muscle weakness (hypotonia) is also common, resulting in delayed motor development (delay in sitting or standing), and closure of the anterior fontanelle is delayed.

Symptoms in childhood (after 2 years)

In childhood, skeletal deformities emerge as the main symptoms. As lower limb deformities, genu varum (bowlegs) or genu valgum (knock-knees) appear when weight bearing begins; these are bending deformities caused by weight bearing on the softened diaphyses. Growth failure persists, and the child is shorter than peers. There is bone pain, with complaints of pain when walking or when the legs are pressed, and gait abnormalities (waddling gait) are observed. As dental symptoms, enamel hypoplasia, delayed tooth eruption, and increased susceptibility to dental caries may appear. Chest deformities (sternal depression or protrusion) can also affect breathing and may be associated with frequent respiratory infections.


7. Signs

Bone and cranial findings

The physical signs of rickets are very specific and of high diagnostic value. Craniotabes is characteristically observed in infancy: when the temporal and parietal bones are lightly pressed and released, there is a sensation like pressing a ping-pong ball (table tennis ball sensation), described as a 'ping-pong ball skull'. Frontal and parietal bossing is a finding in which the forehead and crown become prominent due to accumulation of unmineralized bone matrix. Rachitic rosary is a characteristic finding in which enlargement of the costochondral junctions is palpable like a string of beads, confirmed by inspection and palpation of the chest. Harrison's groove is a horizontal depression of the chest wall at the diaphragmatic insertion, caused by the diaphragm pulling on the softened chest wall during breathing.

Limb and biochemical findings

Epiphyseal enlargement of the wrists and ankles is confirmed by inspection and palpation, reflecting abnormal widening of the growth plates. Lower limb deformities (genu varum or genu valgum) appear as weight bearing begins. In tests of neuromuscular hyperexcitability, Chvostek sign (tapping the cheek near the facial nerve causes contraction of the ipsilateral facial muscles) and Trousseau sign (carpopedal spasm when a blood pressure cuff is inflated above systolic pressure for 3 minutes or more) may be positive.

Biochemical findings are characterized by markedly elevated serum ALP (the most sensitive indicator of bone dysplasia), low or low-normal serum Ca (may remain normal early due to PTH compensation), low serum Pi, serum 25(OH)D <20ng/mL (deficiency), and markedly elevated serum PTH. Urinalysis shows a decreased urine calcium/creatinine ratio and increased urinary phosphate excretion. X-rays show cupping and fraying deformities of the growth plates, increased growth plate width, decreased bone density, bowing of the diaphyses, and rarely Looser zones (incomplete fracture lines).


8. Screening

Screening of high-risk groups

Routine screening for nutritional rickets is not performed in all children, but active screening is recommended in high-risk groups. High-risk groups are as follows: (1) exclusively breastfed infants without vitamin D supplementation, (2) children with dark skin (more melanin), (3) environments with very little sun exposure (predominantly indoor living, high-latitude regions), (4) accompanying fat malabsorption disorders (Crohn's disease, celiac disease), (5) children on long-term antiepileptic or antituberculosis drugs. In these high-risk groups, serum 25(OH)D, serum ALP, Ca, Pi, PTH are measured selectively. Elevated serum ALP can be the first biochemical indicator of early rickets even when the vitamin D level measures at the low end of normal, so when ALP elevation is confirmed, rechecking 25(OH)D is needed.

Newborn and family history-based screening

In newborns with a family history of hereditary rickets (VDDR1, VDDR2, XLH), serum electrolytes, ALP, 25(OH)D, and PTH are measured early after birth and genetic testing is performed. In children of patients in the family already confirmed to have XLH, serum Pi measurement and bone X-rays are performed from the first year of life to gain the opportunity for early treatment. Prenatal genetic testing (chorionic villus sampling or amniocentesis) is also technically possible, but because VDDR and XLH are treatable diseases, the clinical application of prenatal diagnosis is limited.


9. Diagnosis

Biochemical diagnosis

The biochemical diagnosis of rickets begins with a basic panel including serum 25(OH)D, ALP, Ca, Pi, and PTH. Serum 25(OH)D is the optimal indicator reflecting vitamin D status, with less than 20ng/mL (50nmol/L) defined as deficiency and less than 12ng/mL as severe deficiency. However, even if 25(OH)D is at a borderline value, functional vitamin D deficiency can be determined if ALP is markedly elevated. Serum ALP is the most sensitive biochemical indicator in rickets, rising to several times the age-specific normal range. Serum Ca is normal or low-normal early owing to PTH compensation, but hypocalcemia appears when the limit of compensation is reached. Serum Pi is low due to increased renal phosphate excretion from secondary hyperparathyroidism. Serum PTH is elevated due to secondary hyperparathyroidism.

For differentiating causes, measurement of serum 1,25(OH)₂D (calcitriol) is important for distinguishing VDDR1 (low) from VDDR2 (very high). Serum FGF-23 measurement is used to differentiate hypophosphatemic rickets such as XLH. Urine calcium/creatinine ratio (to differentiate Fanconi syndrome, Dent disease, etc.) and measurement of the tubular reabsorption of phosphate (TRP) also help identify the cause.

Imaging and molecular diagnosis

Plain X-rays of the wrists and knees are the key imaging test in the diagnosis of rickets. Cupping and fraying deformities of the growth plates, increased growth plate width (normal 3mm or more), metaphyseal irregularity, decreased bone density, and fracture lines are characteristic. Chest X-ray shows the rachitic rosary and chest deformities. Skull X-ray shows ping-pong ball skull findings (skull softening) and delayed closure of the cranial sutures. When hereditary rickets is suspected, genetic testing is performed by NGS rickets panel including CYP27B1, VDR, PHEX, FGF23, ENPP1, etc.


10. Treatment

Vitamin D and calcium supplementation in nutritional rickets

The cornerstone of treatment for nutritional rickets is vitamin D and calcium supplementation. There are two methods of administering vitamin D. Daily dosing: cholecalciferol (D₃) or ergocalciferol (D₂) 2,000–6,000IU/day for 2–3 months, then switching to a maintenance dose (400–1,000IU/day). Stoss therapy: single high-dose administration (150,000–600,000IU given once or divided over several weeks), used to improve adherence in settings with poor access to medical care. According to the Global Consensus recommendations, stoss therapy shows effects similar to daily dosing, but caution is needed because of a risk of transient hypercalcemia in some patients.

Calcium supplementation is recommended together with vitamin D treatment. The Global Consensus recommendations advise giving 500mg/day of calcium from the diet or supplements together with treatment of nutritional rickets. In calcium deficiency rickets (African type), calcium supplementation is more important than vitamin D supplementation, and calcium 500–1,000mg/day is combined with vitamin D. To monitor treatment response, serum ALP, Ca, Pi, and PTH are remeasured 1–3 months after starting treatment and follow-up X-rays are performed. A decrease in ALP and improvement of radiographic findings are indicators of treatment effect.

Specific treatment of hereditary rickets

In VDDR1 (CYP27B1 deficiency), calcitriol (1,25(OH)₂D₃, 0.25–2μg/day) is administered to bypass the enzyme deficiency. In VDDR2 (VDR deficiency), very high-dose calcitriol (up to 6μg/kg/day) and calcium supplementation are tried, but long-term continuous intravenous calcium infusion is sometimes needed. In XLH (PHEX deficiency), oral phosphate supplementation (divided into 5 doses/day) combined with calcitriol has traditionally been used, but recently the FGF-23 neutralizing antibody burosumab (Crysvita) was approved as a targeted therapy for XLH and shows superior efficacy to phosphate supplementation therapy. Burosumab is administered by subcutaneous injection and is effective for healing of the growth plates and normalization of serum Pi.


11. Prognosis

Recovery with early treatment

Nutritional rickets has a very good prognosis when vitamin D and calcium supplementation is started after early diagnosis. Biochemical response begins within 1–4 weeks of starting treatment, with serum ALP decreasing and Ca·Pi normalizing. Radiographic improvement is slower: cupping deformities of the growth plates begin to improve after 2–4 months, and most normalize after 6 months to 1 year. Simple skeletal deformities (mild genu varum·genu valgum) can largely correct spontaneously during normalization after treatment, but severe deformities or those after growth plate closure may require surgical correction. Final height after treatment often reaches the normal range with appropriate treatment, but the longer treatment is delayed, the higher the likelihood of permanent growth loss.

Complications and long-term management

With delayed or incomplete treatment, permanent skeletal deformities, growth failure, and dental abnormalities may remain. Episodes of hypocalcemic seizures, if not properly treated, can lead to neurological damage and developmental delay. To prevent recurrence, maintenance vitamin D supplementation (400–1,000IU/day), regular sun exposure, and a balanced diet (foods rich in calcium and vitamin D) should be continued even after treatment. Hereditary rickets (XLH, VDDR) requires long-term treatment, and management of osteomalacia continues into adulthood. In patients with XLH, complications such as hearing loss, dental abscesses, and craniosynostosis can occur, so multidisciplinary management is needed.


12. Prevention

Primary prevention: vitamin D supplementation and dietary management

Prevention of nutritional rickets is effective and highly cost-effective. The most important prevention strategy is to start vitamin D 400IU/day supplementation immediately after birth in all breastfed infants. This is a recommendation of the American Academy of Pediatrics (AAP), the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), and the Korean Society of Pediatric Endocrinology. Formula-fed infants do not need separate supplementation when consuming 1L or more of vitamin D-fortified formula, but 400IU/day supplementation is recommended when consuming less. Vitamin D supplementation for pregnant and breastfeeding women (600–2,000IU/day) is also important, as it increases fetal and neonatal vitamin D stores.

Dietary intervention: education to consume sufficient calcium-rich foods (milk, dairy products, tofu, fish eaten with bones). Intake of vitamin D-fortified milk, fortified orange juice, fortified cereals, etc. is recommended. Sun exposure: 15–30 minutes a day of direct sunlight exposure (early morning or late afternoon, when the UV index is low) helps vitamin D synthesis. However, excessive UV exposure carries a risk of skin cancer, so in infants, vitamin D supplementation is recommended over direct UV exposure.

Secondary and tertiary prevention

Raising awareness among clinicians for screening and early detection in high-risk groups is important. In infants who have experienced a vitamin D deficiency seizure, rickets evaluation and treatment are started immediately. To prevent recurrence after treatment, maintenance supplementation is continued even after completion of treatment, and vitamin D status is checked through regular serum testing. At the community and public health level, vitamin D-fortified food policies, programs providing free vitamin D supplements to infants in vulnerable groups, and education for health care workers and parents are effective tertiary prevention strategies.


13. References

  1. Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab. 2016;101(2):394–415. PMID: 26745253
  2. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc. 2011;86(1):50–60. PMID: 21193656
  3. Pettifor JM. Nutritional rickets: deficiency of vitamin D, calcium, or both? Am J Clin Nutr. 2004;80(6 Suppl):1725S–1729S. PMID: 15585795
  4. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281. PMID: 17634462
  5. Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM. Rickets. Nat Rev Dis Primers. 2017;3:17101. PMID: 29265112
  6. Imel EA, Glorieux FH, Whyte MP, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393(10189):2416–2427. PMID: 31104833
  7. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev. 2016;96(1):365–408. PMID: 26681795
  8. Shore RM, Chesney RW. Rickets: Part I. Pediatr Radiol. 2013;43(2):140–151. PMID: 23085820
  9. Saggese G, Vierucci F, Boot AM, et al. Vitamin D in childhood and adolescence: an expert position statement. Eur J Pediatr. 2015;174(5):565–576. PMID: 25599819
  10. Korean Society of Pediatric Endocrinology. Recommendations for vitamin D supplementation in children and adolescents. Clinical and Experimental Pediatrics. 2022;65(5):287–298. DOI: 10.3345/cep.2022.00174